COMMUNIQUÉS West-GlobeNewswire

Wave Life Sciences to Present at Upcoming Investor Conferences
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
01/06/2026
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs [...]
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
01/06/2026
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics [...]
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
01/06/2026
MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications [...]
Ardena appoints Ariane de Ganck as Chief Scientific Officer
01/06/2026
Ghent, Belgium, June 1, 2026 - Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief [...]
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
01/06/2026
Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is expected to enter a [...]
Solid Biosciences to Participate at Upcoming Investor Conferences
01/06/2026
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
01/06/2026
HELSINKI, June 01, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical-stage biotech developing first-in-class therapies for thromboinflammatory diseases, today announced the comprehensive publication of an invited review [...]
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
01/06/2026
Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain Nociscan’s underlying MRS technology enabled measurement of intradiscal propionic acid to [...]
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
01/06/2026
Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia, unlocking up to $1 [...]
Human Appeal Releases “Thrive with Dignity” Impact Report, Highlighting Support for Over 7.3 Million People Globally
01/06/2026
Key 2025 Impact Highlights Include Human Appeal’s work in: Reaching 7,348,330 people through life-saving aid and long-term programs across 30 countries. Providing emergency aid to 2,761,965 people across 15 countries [...]
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
01/06/2026
REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and offers for ALVO [...]
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
01/06/2026
Analysis from the Phase 3 COMPETE trial suggests population-based modeling may enable accurate individualized dosimetry with substantially fewer imaging requirements Los Angeles, California, June 1, 2026 — ITM Isotope [...]
Rejuvenate Biomed Completes Recruitment in Phase 2 Trial Assessing First-in-Class Multi-Pathway Therapeutic RJx-01 in COPD-Induced Sarcopenia
01/06/2026
Fully recruited Phase 2 trial evaluates RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia, an area with no approved pharmacologic treatments RJx-01 offers a multi-pathway approach targeting several [...]
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
01/06/2026
STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
01/06/2026
Curium’s strategic investment of over €32 million will establish a European production line for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer This investment [...]
IBA lance Cyclone® iKure, un cyclotron conçu pour la production d’Astate-211 à l’échelle industrielle
01/06/2026
Louvain ‑ la ‑ Neuve, Belgique, le 1 er juin 2026 — IBA (Ion Beam Applications S.A., EURONEXT) , leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de [...]
New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
01/06/2026
The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland – June 01, 2026 [...]
IBA launches Cyclone® iKure, a cyclotron designed for industrial scale Astatine-211 production
01/06/2026
Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT) , the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today [...]

Pages